Inclusion-body myositis …

Marinos C Dalakas MD

Neuromuscular Disorders

Updated 02.28.2024
Released 03.23.1994
Expires For CME 02.28.2027

Inclusion body myositis

Author: Marinos C Dalakas MD

See Contributor Disclosures

Editor: Nicholas E Johnson MD MSCI FAAN

Inclusion body myositis

In This Article

Quick Link

Introduction

Overview

Inclusion body myositis is the most frequent and disabling myopathy seen in patients over 45 to 50 years of age. The distinct clinical features that lead to correct diagnosis and the inclusion body myositis mimics are highlighted. Inclusion body myositis has a complex pathogenesis in which autoimmune and inflammatory features coexist with elements of degeneration and abundant accumulations of various stressor proteins. In this article, the author discusses the pitfalls in diagnosis, the diagnostic markers, and the role of inflammation and degeneration in the pathogenesis of the disease, including the interaction between these processes. The latest trends in therapeutic strategies are also presented.

Historical note and terminology

Inclusion body myositis (IBM) was first recognized as a distinct entity between 1967 and 1971. Three groups identified distinct microtubular filamentous inclusions by electron microscopy in the muscle biopsies of some patients with presumed polymyositis (29; 24; 162). The term "inclusion body myositis" was coined to stress the uniqueness of the disease and separate it from polymyositis (162). Carpenter and colleagues’ seminal paper emphasizing the clinical entity (23) brought the disease to the surface and stimulated the interest of a number of investigators, including the author of this article.

Clinical manifestations

Presentation and course

One of the earliest and most frequent symptoms in patients with inclusion body myositis is falling and tripping due to weakness of the quadriceps muscle and foot extensors (104; 33; 150; 35; 122; 43). In other patients, the disease may begin with weakness of the distal muscles of the hands, which manifests as difficulty with fine motor movements such as grasping, pinching, or buttoning. The selective involvement of the flexor digitorum profundus has been confirmed with a magnetic resonance imaging study that was utilized for the first in this disorder (149). Weakness is asymmetrical in one third of patients. Another common symptom is dysphagia, which occurs in up to 40% of the patients by the time of diagnosis (104) but becomes more frequent as the disease progresses, reaching a frequency close to 80% (126), resulting in life-threatening choking episodes and aspiration pneumonias. Dysphagia is due to dysfunction of the upper esophageal muscles and can be demonstrable by a barium swallow examination with videofluoroscopy or by real-time MRI that also visualizes the soft tissues and provides more reliable timing analysis without x-ray exposure (126). In contrast to necrotizing autoimmune myositis and dermatomyositis, where facial muscles are typically spared (37; 38), mild facial weakness is very common in inclusion body myositis and may aid in the diagnosis; extraocular muscles are spared.

About 10% of patients complain of distal weakness as the first symptom, but nearly all have distal weakness at the time of diagnosis (150).

Characteristic clinical features of inclusion body myositis

Patterns of muscle weakness in inclusion body myositis. (A) Wasting of the forearm muscles (*) with difficulty making a grip. (B) Quadriceps atrophy (*). (C) “Locking up” of the knee to avoid falls and use of a cane. (D) Dyspha...

The quadriceps muscle is typically involved early in the disease, with wasting and weakness. This accounts for the high frequency of falling and for the characteristic "locked knee" gait, which aids in stabilizing the leg in the presence of quadriceps weakness (33; 43). A small number of patients, however, may have intact quadriceps, which in younger patients may generate diagnostic dilemmas in distinguishing sporadic inclusion body myositis from the hereditary, GNE-related, quadriceps-sparing form. Tendon reflexes are normal or diminished; patellar and ankle reflexes are typically depressed early, owing to atrophy of the quadriceps and gastrocnemius muscle. The depressed ankle reflexes have been one of the reasons for misdiagnosing the disorder as neurogenic (often as lower motor neuron disease) or for suggesting that it coexists with a neuropathic process.

Sensory examination is generally normal; however, mildly diminished vibratory sensation in the lower extremities, possibly related to the patients' ages or coexisting conditions, can be seen. Although neurogenic findings on electrophysiological studies have been reported in some patients, no definitive clinical signs of neuropathy exist, despite the distal muscle involvement. The involvement of the distal muscles in inclusion body myositis is due to the myopathic process, as confirmed with macro EMG studies (105). Inclusion body myositis should, therefore, be viewed as both a proximal and distal myopathy. In patients with inclusion body myositis, the weakness progresses slowly over years, and it is associated with worsening atrophy of the weak muscles. Progression to disability appears to occur more rapidly when symptoms begin after 60 years of age (128). In a 12-year follow-up study conducted in the Netherlands, the mean decline in strength was 3.5% per year according to the manual muscle strength testing, with more pronounced weakness in the legs (30). Life expectancy was normal at 81 years, but activities of daily life were restricted; all patients required a wheelchair in the end.

Prognosis and complications

Inclusion body myositis is a slow, but relentlessly progressive, myopathy. At worst, patients will become confined to a wheelchair. The degree of disability worsens with time. In an early series of 14 patients with symptoms for more than 5 years who were carefully followed, 10 patients required a cane or support for ambulation by the fifth year after onset of disease; three of five patients with symptoms for 10 years or more were essentially confined to wheelchairs (150). Dysphagia can also be disabling for a number of patients, representing one of the commonest causes of autoimmune neurogenic dysphagia (46). New data from Sweden showed that inclusion body myositis may also have an early onset, at the median age of 36 (range 34–45), with more severe disease and worse prognosis (102). However, this contrasts with another study from Hopkins that showed that younger age (< 50 years) at onset is not associated with increased weakness (113), an observation consistent with this author’s experience.

Biological basis

Etiology and pathogenesis

The cause of inclusion body myositis remains elusive, and the factors triggering immune and protein dysregulation or vacuolar formation remain unknown. In addition to T cell-mediated cytotoxicity, there are also degenerative features consisting of vacuoles and accumulation of amyloid-related proteins. Whether the primary event is autoimmune or degenerative is a matter of debate as extensively addressed below.

Sporadic inclusion body myositis should not be confused with the hereditary forms that lack endomysial inflammation and occur in younger-aged patients (152; 08). Among these heterogeneous groups of patients, there is a distinct autosomal recessive hereditary inclusion-body myopathy that typically presents with distal lower extremity weakness that spares the quadriceps muscles, even when other proximal muscles are affected. This entity, sometimes referred to as "quadriceps-sparing myopathy," but now called GNE-myopathy because the cause is known, was initially described in patients of Iranian Jewish descent, but it is now detected in many ethnic groups (06; 64; 158). It is associated with mutations in the UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase (GNE) gene on chromosome 9 (64; 87; 124); hence, the correct name is “GNE-myopathy.” Another type of hereditary inclusion-body myopathy is that seen in patients with Paget disease, which is linked to mutations in the valosin-containing protein (160).

The two main hallmarks in the pathology of inclusion body myositis are the presence of T cells invading intact (nonvacuolated) fibers and the vacuolar degeneration with congophilic deposits, mostly occurring in fibers not invaded by T cells and suggesting that a primary immune process and a degenerative process may occur independently or in concert with each other.

Typical muscle biopsy findings in inclusion body myositis

(A) Cross-sections of H&E-stained muscle biopsies demonstrate scattered inflammatory foci with lymphocytes invading or surrounding healthy-appearing muscle fibers combined with autophagic vacuoles with bluish-red material i...
Typical immunopathology of inclusion body myositis

MHC-1/CD8 complex in inclusion body myositis. (A) The cells surrounding or invading healthy muscle fibers are CD8+T cells, seen in green, immunostained with an anti-CD8+ monoclonal antibody (x640). (B) There is also widespread ...

The endomysial inflammation, which is prominent from the outset and may persist even late in the disease, is identical to that originally described as polymyositis, where CD8-positive cells predominate (04; 04; 05). A number of the CD8-positive cells are cytotoxic, containing perforin granules (146), and focally surround and invade healthy muscle fibers that aberrantly express the major histocompatibility complex (MHC) class I antigen (85; 65; 35).

These cells are primed to receive specific antigenic peptides presented by the MHC class I molecule, forming immunological synapses as confirmed by the upregulation of the B7 family of molecules (B7-1, B7-2, BB-1, ICOS-L, and CD40) on muscle fibers and their respective counter-receptors (CD28, CTLA-4, ICOS, and CD40-L) on the CD8-positive cells (115; 146; 161; 35; 43). The upregulation of MHC class I in inclusion body myositis is ubiquitous and differs from the patchy and focal expression limited to the areas of necrosis or lymphocytic invasion, as seen in dystrophies. Further, MHC-I overexpression can induce cell stress via upregulation of proteins involved in the endoplasmic reticulum (119). Laser microdissection studies have shown that MHC-1 upregulation is triggered prior to inflammation, and there is differential upregulation of several interferon-gamma-induced genes in the fibers invaded by T cells (81). In inclusion body myositis, the autoinvasive CD8-positive T cells persist over time and appear antigen-driven because they are clonally restricted, expressing a limited number of T-cell receptor gene rearrangements (03). Spectratyping of the CDR3 region of the T-cell receptor V beta chains in lymphocytes confirmed the clonality of T cells in inclusion body myositis (60). Studies on lymphocytes obtained concurrently from the peripheral blood and the muscles has further concluded that the clonal expansion of the autoinvasive T cells occurs in situ, within the muscle microenvironment, probably after recognizing local antigens (138). Evidence also suggests that the disease may also be associated with T-cell large granular lymphocytic infiltrates, similar to those seen in T-cell large granular lymphocytic leukemia (73). In addition to T cells, the inflammatory cell infiltrates also contain plasma cells, dendritic cells, and clonally expanded B cells, indicating that different effector mechanisms of T and B cells concurrently play an active role in the autoimmune process (20). Data based on genomic datasets across T-cell differentiation states suggest that in inclusion body myositis there are highly differentiated CD8+CD57+ T cells with cytotoxicity profile expressing the killer cell lectin-like receptor G1 (KLRG1) (70). This observation, although of unknown pathogenic significance, further strengthens the view that the autoinvasive endomysial T cells are highly differentiated cytotoxic T cells based on their expression of perforin and granzyme granules (146). A subpopulation of KLRG1 T cells also seems to be expanded among the circulating blood mononuclear cells of patients with inclusion body myositis (69), but its significance in reference to disease duration or severity remains to be investigated. Because the KLRG1+ CD8+ T cells are highly differentiated cytotoxic cells and over-represented in the blood of patients with inclusion body myositis, it was proposed that a trial with a monoclonal antibody targeting KLRG1 could deplete the cells that infiltrate the inclusion body myositis muscle; however, whether such depletion will be of clinical significance in improving the patients’ clinical course is quite uncertain.

Cytokines, cytokine signaling, chemokines, and metalloproteinases are also prominent on the muscle fibers (57; 58), with upregulation of the cytotoxic tandem HSP90/iNOS in the inflammatory cells invading muscle fibers (59). Interestingly, the human muscle, in vivo and in vitro, can also secrete proinflammatory cytokines on cytokine stimulation in an autoamplificatory mechanism, which facilitates the recruitment of activated T cells to the muscle and contributes to the self-sustaining nature of endomysial inflammation (146; 141; 161; 35; 143; 144). It has been collectively proposed that a joint action of chemokines and cytotoxic factors in cytotoxic T-cells, macrophages, and myeloid dendritic cells leads to the demise of the myofibers (59).

Humoral factors also seem to play a role as exemplified by observations of isolated single plasma cells from inclusion body myositis muscle sections. A series of recombinant immunoglobulins reconstructed from these cells recognized self-antigens expressed by cell lines and in muscle tissue homogenates (132). One of the putative antigens is identified as the 5’-nucleotidase 1A (anti- cN1A), an enzyme involved in nucleotide metabolism that is highly expressed in skeletal muscle. Anti- cN1A antibodies were detected in 33% to 50% of patients with inclusion body myositis (95; 129; 156). Even if these antibodies may not have distinct specificity for inclusion body myositis as they are also observed with lower frequency in other autoimmune diseases (107), their presence strengthens the view of a humoral immune response. Using an in vitro and in vivo passive immunization model, it was further found that the anti-cN1A antibodies may affect protein degradation in myofibers (156). Of relevance, the presence of these antibodies is associated with robust production of immunoglobulin transcripts derived from intramuscular CD19+ plasmablasts and clonal CD138+ plasma cells (70).

Congophilic material, best visualized by Texas red fluorescence optics, can be found in a variable number of fibers usually in or near rimmed vacuoles (112; 10). However, this is by no means specific for inclusion body myositis as it has been found in other vacuolar myopathies or even in vacuolated fibers in chronic neurogenic conditions, such as postpolio syndrome (39). The same applies to a variety of molecules, such as beta amyloid and its precursor protein alpha-chymotrypsin, tau proteins, and apolipoprotein E, which are found in a small percentage of fibers (67). In inclusion body myositis, the beta amyloid appears targeted for lysosomal degradation via macroautophagy (106). The overexpression of the stressor protein alpha B-crystallin in intact fibers (named X-fibers) has also been of interest as an early stressor event preceding degeneration (15). Additional data suggest that alpha B-crystallin is associated with overexpression of amyloid precursor protein in the sIBM muscles and that upregulation of alpha B-crystallin precedes accumulation of beta amyloid (118). Laboratory studies have shown that within the X-fibers there is nitric oxide (NO)-associated cell stress that precedes degeneration, whereas the majority of the fibers display intracellular accumulation of amyloid (142).

The overexpression of beta-amyloid precursor protein in the muscles of patients with inclusion body myositis has led some investigators to propose that the pathogenesis of inclusion body myositis may be similar to that of Alzheimer disease (08; 09; 11). Overexpressing beta-amyloid precursor protein in cultured human muscle and transgenic mice models has produced pathologic findings resembling those seen in inclusion body myositis (08; 89). The precise role of beta-amyloid precursor protein in the pathogenesis of inclusion body myositis, however, remains unclear. It has been proposed that the accumulation of beta amyloid and the related proteins appears to result from protein misfolding (67; 68; 11). The elevated levels of mutant ubiquitin noted in the muscles of these patients may result in the aggregation of beta amyloid and phosphorylated tau by inhibiting cellular housekeeping enzymes (the proteosome), as proposed in Alzheimer disease. Deposits of TDP43, a DNA-binding protein aberrantly translocated from the nuclei to the cytoplasm, and p62, a shuttle protein that transports polyubiquitinated proteins, detected within the muscle fibers with the use of immunostaining, have been advocated as diagnostic markers (137; 12). Although in vitro evidence suggests that amyloid-β42 and its oligomers may be involved in the pathway of intracellular toxicity, it remains unclear how these proteinaceous aggregates, which are also seen in other vacuolar myopathies, induce an inflammatory and degenerative myopathy and what triggers disease, inflammation, or protein aggregation (43). Compelling evidence suggests that aging, abnormal proteostasis (the network controlling proteins), impaired autophagy, cell stress induced by MHC class I or nitric oxide, long-standing inflammation, and proinflammatory cytokines such as interferon-γ and interleukin-1β may cumulatively trigger or enhance degeneration, leading to further accumulation of stressor molecules and misfolded proteins (43).

The origin of the vacuoles remains uncertain. Two hypotheses have been proposed for their formation: (1) they develop as a consequence of abnormal lysosomal function, or (2) they develop in association with the breakdown of myonuclei, based on the observation that components of myonuclei are present in the rimmed vacuoles of patients with inclusion body myositis by immunohistochemistry and electron microscopy (72). However, both of these hypotheses lack functional studies and remain speculative. The nuclear products found within the cytoplasm are more likely to be secondary to lysosomal degradation and muscle fiber degeneration. A study using laser microdissection of fibers with rimmed vacuoles and mass spectrometry showed that proteins associated with protein folding and autophagy were the largest group represented among 213 identified proteins (75). One autophagic adaptor protein was the FYVE and coiled-coil domain-containing protein 1 (FYCO1), which functionally connects autophagic and endocytic pathways. FYCO1 colocalized at the rimmed vacuoles with key autophagic proteins; it lacked, however, specificity for inclusion body myositis because it was also observed in other vacuolar myopathies. In spite of this limitation, the study provides interesting data supporting the previous coined hypothesis that impaired autophagic function may lead to vacuolar formation and that in inclusion body myositis there is impaired endolysosmal degradation (75).

As filamentous and eosinophilic inclusions are characteristically seen in paramyxovirus-infected cell cultures, a viral etiology for inclusion body myositis has been suggested since the initial recognition of the disease (28; 24). However, paramyxovirus nucleic acid has never been detected in muscle biopsy specimens by in situ hybridization or by polymerase chain reaction (123; 83; 98). Furthermore, no significant elevations of mumps antibody titer have been demonstrated in the serum of inclusion body myositis patients, and mumps virus has not been isolated in tissue cultures obtained from these patients’ muscles (24; 140; 114). Very sensitive PCR studies have repeatedly failed to confirm the presence of viruses in the patients’ muscle biopsies, suggesting that known viruses do not seem to replicate in the inclusion body myositis muscles (98; 99). The most tantalizing observation, however, is the association of inclusion body myositis with HIV and HTLV-I infections. The observation, originally made in only three patients (31), was later confirmed throughout the world in many patients (77), including seven additional patients from our own laboratory (34; 52). In HIV/HTLV-I seropositive patients, the disease appears several years after the first manifestations of the retroviral infection, suggesting that inclusion body myositis is more frequently recognized as patients live longer and harbor the virus for several years. The virus is not, however, present within the muscle fibers but only in occasional macrophages around muscle fibers. In HIV-associated inclusion body myositis, the endomysial CD8-positive cytotoxic T cells that surround or invade the fibers are clonally expanded, and their T cell receptors contain amino acid residues for specific HLA/viral peptides. Although there is no evidence of viral replication within the muscle fibers in HIV/HTLV-I inclusion body myositis, the chronic retroviral infection appears to trigger a persistent, viral-specific inflammatory response that eventually leads, via unknown mechanisms, to the clinicohistological phenotype of sporadic inclusion body myositis (127; 52). This convincing observation supports the hypothesis for the potential role of other chronic viral infections in the development of inclusion body myositis. An association with hepatitis C has been observed in a large number of Japanese patients (157). Because hepatitis C remains high (at 3.2%) in people born between 1945 to 1965, the ages where inclusion body myositis is more common, screening for hepatitis C has been suggested for these age groups, especially because hepatitis C is often silent and the original infection asymptomatic (53). In the present SARS-CoV-2 pandemic, there is no convincing evidence that the virus can infect human muscle or cause inclusion body myositis, although theoretically, it may have the potential of triggering an inflammatory process like other viruses (44; 45; 46).

Mitochondrial abnormalities, including mitochondrial DNA deletions, ragged-red fibers, and deficient cytochrome oxidase staining, are well-described findings in the muscle of patients with inclusion body myositis (74; 19; 35). Interestingly, these abnormalities are seen in sporadic inclusion body myositis but not in hereditary inclusion-body myopathy. There is now evidence that in the muscles of inclusion body myositis the pathological markers TDP-43, phosphorylated TDP-43, and p62 coexist with intensively stained key subunits of mitochondrial oxidative phosphorylation complexes IV, pointing to a close association of TDP-43 accumulation with mitochondria in degenerating muscle fibers (79). Whether this association contributes to the development of mitochondrial dysfunction and the pathological protein aggregates, as suggested, remains to be determined. The level of mitochondrial DNA (mtDNA) was also found depleted as the muscle of patients with inclusion body myositis contained on average 67% less mtDNA than healthy controls (18).

Regardless of whether the primary event in inclusion body myositis is a dysimmune or protein dysregulation process, there is now strong evidence that proinflammatory cytokines not only correlate with the intramuscular accumulation of amyloid, phosphorylated tau, ubiquitin, and alpha B-crystallin (141; 118), but they also induce tau phosphorylation and amyloid aggregates in vitro. Cytokines also stimulate myofibers to produce inflammatory mediators in an autoamplificatory mechanism, enhancing further the chronicity of inflammation, amyloid formation, and cell stress (43; 88; 32). In an inclusion body myositis model, inflammation also induced degeneration (90). Work from our laboratory has further confirmed that the inducible nitric oxide synthase is a central component in myotoxicity of inclusion body myositis enhanced by the interactions of interleukin-1 and interferon-gamma (142). Further, blockade of nitric oxide production diminishes the accumulation of amyloid and subsequent cell death. Until the cause of inclusion body myositis is identified, these associations may impact therapeutic directions (36; 37; 145). RNA sequencing analysis of muscle biopsy samples from patients with inclusion body myositis showed overexpression of cadherin 1, but its significance remains entirely uncertain (80).

Although the view that the autoimmune and degenerative process coexist and amplify each other remains strong (43), the debate still continues as to which is the primary process. Based on the aforementioned studies, the evidence pointing to the inflammatory-autoimmune process as the primary culprit leading to muscle degeneration is summarized on the following points (34; 143; 144; 40; 145; 70; 32):

	(1) Inclusion body myositis is associated with autoantibodies, paraproteins, immunodeficiency, and other systemic autoimmune or connective tissue diseases in up to 33% of affected patients (104; 47; 48; 91; 14). Data also confirm an increased association with Sjogren syndrome, other autoimmune diseases, and autoantibodies (134; 133; 129).
	(2) Frequent immunogenetic association with the HLA-B8-DR3 haplotype and increased frequency of DRb10301 and DQb10201 alleles associated with DR and DQ phenotypes have been documented in up to 75% of patients (92; 14). This frequency is similar to that noted in other autoimmune diseases, such as myasthenia gravis and Lambert-Eaton myasthenic syndrome (14). There is also evidence that the mean age at onset is 6.5 years earlier in DRB103/01 heterozygotes patients who also have more severe quadriceps muscle weakness (110; 148). These associations indicate that interactions between the HLA-DRB1*03 allele and other alleles at the DRB1 locus can influence disease susceptibility. Inclusion body myositis with the typical clinical and immunopathological features of sporadic inclusion body myositis has also occurred in family members of the same generation who have the same immunogenetic background, a phenomenon known to occur in other autoimmune disorders; such familial aggregation has been designated “familial inflammatory inclusion body myositis” (153).
	(3) Inclusion body myositis is increasingly seen with HIV and HTLV-I infection with viral-specific endomysial inflammatory cells, an association that is more than chance (31; 34; 52; 77).
	(4) T-cell invasion of nonnecrotic fibers is found early in the disease and at a higher frequency than in the Congo red-positive fibers with degenerative features (130).
	(5) Endomysial inflammation alone, as seen in polymyositis, is known to cause muscle destruction and clinical weakness; whether the small beta-amyloid deposits and other aggregates in some fibers are sufficient to trigger muscle degeneration remains unclear (37a; 37b; 40; 42). Of interest, up to 15% of patients with the clinical phenotype of inclusion body myositis have no vacuoles or deposits of misfolded proteins, as discussed below.
	(6) There is evidence that in inclusion body myositis a humoral immune response in both the periphery and at the site of tissue damage also takes place and is directed towards self-antigens (132; 129; 95). The patients have not only higher incidence of 5’-nucleotidase 1A (anti- anti-cN1A) antibodies but their presence is also associated with robust production of immunoglobulin transcripts derived from intramuscular CD19+ plasmablasts and clonal CD138+ plasma cells (70).
	(7) In inclusion body myositis the autoinvasive endomysial T cells are highly differentiated cytotoxic T cells with features similar to those present in large granular lymphocytic leukemia, as well as highly differentiated CD8+CD57+ T cells with cytotoxicity profile expressing the killer cell lectin-like receptor G1 (KLRG1) (70).
	(8) There is abundant accumulation of potent cytotoxic cytokines connected to T cell activation process.

On the other side, there is also evidence favoring the view that inclusion body myositis is a degenerative disease and that the inflammatory features are secondary (09; 12), based on the following points:

	(1) Inclusion body myositis is resistant to immunomodulating therapies. Although this is true, it can be counter-argued that a number of chronic autoimmune conditions with CD8+ T cell-mediated damage, such as primary progressive multiple sclerosis, chronic rheumatoid arthritis, systemic lupus erythematosus, Sjögren syndrome, and primary biliary cholangitis are also resistant or do not sufficiently respond to immunotherapies. Accordingly, the refractoriness of inclusion body myositis to immune therapies should not be interpreted against an autoimmune process but rather as due to the presence of distinct autoimmunity with highly differentiated nonproliferating cytotoxic T cell phenotypes, as summarized by Greenberg (70). It is likely that some of the previous treatment strategies with potent immunomodulators like alemtuzumab might have shown limited efficacy because they exerted a broad nonselective lymphocytic depletion (51; 70) instead of targeting the highly differentiated cytotoxic T cells.
	(2) There is a strong presence of degenerative features highlighted by rimmed vacuoles, intracellular deposition of stressor molecules, and Congo red-positive amyloid, including beta-amyloid-related molecules such as beta-amyloid precursor protein, phosphorylated tau, presenilin-1, apolipoprotein Ε, gamma-tubulin, clusterin, alpha-synuclein, or gelsolin (11; 09; 12). These accumulations are prominent but not unique to sporadic inclusion body myositis because they are also observed to a similar extent in other nonimmune, hereditary, or acquired vacuolar myopathies, especially myofibrillar myopathies that lack inflammation. Whether the accumulation of misfolded proteins is the primary culprit leading to vacuolar degeneration has not been proven. The suggestion that these proteins may act as neoantigens triggering a cytotoxic lymphocytic attack on muscle fibers remains hypothetical because there is no evidence that these aggregates induce cytotoxic T-cell infiltrates or that the autoinvasive T cells are sensitized to recognize any of the accumulated molecules within the muscles of inclusion body myositis.
	(3) There is evidence that the initial change occurs in the nuclei because of intranuclear accumulation of tubular filaments representing altered elements of the myonuclear matrix (120; 84; 37). Based on this view, the disintegration of myonuclei release nuclear contents into the cytoplasm and cause rimmed vacuoles owing to the highly basophilic nuclear content in the neutral pH cytoplasm. Although this theory has never been tested and cannot explain the primary cytotoxic T-cell activation, the presence of antibodies against 5’-nucleotidase 1A in degenerating myonuclei provides an indirect support of nuclear involvement (72).
	(4) Mouse models over-expressing amyloid proteins develop muscle weakness, with vacuoles and increased proteasome or autophagic markers in the muscle biopsies, similar to those seen in human inclusion body myositis, but without any of the inflammatory infiltrates or the immune features seen in the human disease.

Differential diagnosis

Inclusion body myositis should be distinguished from the following conditions: (a) inflammatory myopathy characterized as polymyositis, especially when vacuoles are not present; (b) the groups of distal myopathies with rimmed vacuoles, especially myofibrillar myopathies and the GNE-related hereditary inclusion-body myopathy; (c) adult-onset inflammatory dystrophies such as facioscapulohumeral muscular dystrophy or those due to dysferlin and calpain; and (d) amyotrophic lateral sclerosis (as discussed below).

Inclusion body myositis is best distinguished from polymyositis by the pattern of weakness, although the existence of this entity as a distinct subtype has been now disputed (43; 45). Histologically, the presence of rimmed vacuoles, inflammation with CD8-positive cells and ubiquitous MHC-I expression, Congo red-positive deposits, and presence of COX-negative fibers solidify the diagnosis. However, there are a number of cases, up to 15%, with the typical clinical features of inclusion body myositis whose biopsies demonstrate inflammation similar to that seen in polymyositis, but without vacuoles (17; 35; 25; 43); these patients have been designated as having “probable inclusion body myositis,” “polymyositis/inclusion body myositis,” or “clinical inclusion body myositis,” but they are often misdiagnosed with polymyositis. Such errors can be avoided by a combined evaluation of the clinical with the histological and immunopathological findings (25; 37; 42; 45). In spite of the absence of vacuoles, careful review of these biopsies shows a large number of COX-negative fibers and signs of chronicity (large fibers, splitting, increased connective tissue), as seen in inclusion body myositis; a repeat biopsy oftentimes confirms the diagnosis (35). Patients with clinical inclusion body myositis show the same poor response to immunomodulating therapy as do those with "biopsy-confirmed" inclusion body myositis (19). Such cases probably suggest that the inclusion body myositis phenotype and the resulting weakness may not be much related to the vacuolar degeneration.

Many hereditary myopathies, such as oculopharyngeal muscular dystrophy and facioscapulohumeral muscular dystrophy, inclusion-body myopathies due to GNE mutations, and myofibrillar myopathies may have histologic features suggestive of inclusion body myositis. These cases should be suspected when inflammation and ubiquitous MHC expression are absent, and the clinical phenotype is not typical of inclusion body myositis. Staining for MHC/CD8 complex is helpful to distinguish inclusion body myositis from inflammatory dystrophies: in the latter, MHC-I expression is spotty, whereas the majority of the autoinvasive cells are not CD8 but macrophages or other lymphoid cells.

Diagnostic workup

Clinically suspected inclusion body myositis is confirmed by serum muscle enzymes, electromyography, and, above all, by the muscle biopsy that demonstrates characteristic morphological findings.

Creatine kinase is mildly (2- to 3-fold) to moderately (up to 10-fold) elevated. Occasionally, creatine kinase may increase 20-fold, whereas it may be normal in some patients. Other laboratory abnormalities, including markers for autoimmune diseases, can be seen in at least one third of patients.

Electromyography is more important to exclude neurogenic conditions than to confirm the diagnosis of inclusion body myositis body myositis. Inclusion body myositis body myositis may be misdiagnosed as amyotrophic lateral sclerosis because of the asymmetric weakness, atrophy, the normal sensation, and the abundance of spontaneous activity characterized by positive sharp waves and fibrillation potentials, but no fasciculations. However, the presence of myopathic potentials (brief duration and small amplitude polyphasic units), especially in distal muscles, should cause one to suspect a distal myopathy.

In approximately one third of the patients, some "neurogenic" motor unit action potentials of long duration and increased amplitude are interspersed with the myopathic units (82). This pattern, which can also be seen in some patients with longstanding myopathies, probably reflects disease chronicity rather than disease specificity.

Nerve conduction studies are usually normal. Although a coexisting mild axonal sensory polyneuropathy has been reported in some series (63; 104; 100; 07), quantitative EMG or macro EMG studies have detected no evidence of neurogenic involvement (21; 105; 16).

Ultrasound of the forearm was suggested as a useful means in diagnosing the disease although the study was small and still preliminary (86).

The most specific diagnostic test for inclusion body myositis body myositis is the muscle biopsy. The characteristic light microscopic findings are rimmed vacuoles, endomysial inflammation, MHC-I class expression, Congophilic deposits, scattered atrophic fibers, hypertrophic fibers (similar to those seen in chronic dystrophic processes but not in polymyositis), COX-negative fibers with occasional ragged-red fibers, and eosinophilic cytoplasmic inclusions (35; 12; 43).

Typical muscle biopsy findings in inclusion body myositis

(A) Cross-sections of H&E-stained muscle biopsies demonstrate scattered inflammatory foci with lymphocytes invading or surrounding healthy-appearing muscle fibers combined with autophagic vacuoles with bluish-red material i...
Typical immunopathology of inclusion body myositis

MHC-1/CD8 complex in inclusion body myositis. (A) The cells surrounding or invading healthy muscle fibers are CD8+T cells, seen in green, immunostained with an anti-CD8+ monoclonal antibody (x640). (B) There is also widespread ...

The presence of all these features, combined with the typical clinical phenotype, negate the need to perform electron microscopy or immunostaining using “specific” markers whose diagnostic specificity is presently unsettled.

As elaborated above, the inflammation seen in inclusion body myositis body myositis is a primary endomysial process with CD8-positive cells surrounding or invading non-necrotic muscles fibers. The invasion of non-necrotic muscle fibers by mononuclear cells is two to five times more frequent than the invasion of necrotic fibers (130), an observation that implies a primary role of the inflammatory cells in muscle fiber destruction. The autophagic-rimmed vacuoles are present in 2% to 70% of the muscle fibers. A single fiber may contain one vacuole or multiple vacuoles located centrally or in the subsarcolemmal region (22; 130). The granular rim is basophilic by hematoxylin and eosin, and red by the modified Gomori trichrome stain. If the muscle biopsy specimen is embedded in paraffin, the vacuoles may be missed because the granules dissolve during this process (this is probably one of the reasons inclusion body myositis body myositis was overlooked prior to routine processing of muscle for frozen sections). These vacuoles contain cytoplasmic degradation products, such as membranous whorls, myeloid structures, and filaments (23; 37; 42). Most of the vacuolated fibers are positive with acid phosphatase reaction, but the intensity of the staining is not as prominent as in acid maltase deficiency or in some toxic myopathies. With crystal violet or Congo red stains, a small amount of amyloid-positive material is present within, or next to, the vacuoles (112). The reported high specificity of immunostaining with antibodies against SMI-31, p62, and TDP-43 (137; 12) and the suggestion that they may be useful diagnostic markers is unclear because these antibodies also identify markers in other vacuolar myopathies and myofibrillar myopathies, the two most important diseases often misdiagnosed as inclusion body myositis body myositis. Further, these markers are not helpful in the 15% of patients with “clinical inclusion body myositis body myositis” that lack vacuoles, and they are often misdiagnosed as polymyositis. By electron microscopy, the eosinophilic inclusions appear to correspond to collections of 12 to 18 nm intranuclear or cytoplasmic filaments (28; 29; 24; 162; 74). Proposed stains that offer specific markers for inclusion body myositis body myositis are of interest, provided they are validated with large samples and more disease controls (09).

A study has explored PET imaging using Pittsburgh compound B-positron emission tomography (PIB-PET) based on the accumulation of amyloid-beta among the multiple-protein aggregates within the muscle fibers of patients with sporadic inclusion body myositis body myositis (125). The authors reported that muscle PIB-PET may help in the diagnosis of sporadic inclusion body myositis. A prospective observational study showed that quantitative MRI (qMRI), a noninvasive assessment tool, may have the potential to quantify muscle pathologic processes, demonstrating that deterioration in qMRI muscle quality measures over 1 year was associated with a decline in physical performance (96).

Management

To date, no consistently effective treatment for inclusion body myositis body myositis is available. The disease is steroid resistant. In anecdotal reports, some patients may feel stronger early in the disease, but these benefits are limited and do not change the relentless disease progression. Most of the time, however, a reported slight improvement with corticosteroid therapy refers primarily to a perceived worsening of the disease after stopping the therapy, rather than an improvement during therapy. In patients with other associated immune diseases, such as Sjogren syndrome, there appears to be more consistent improvement (134). Other immunosuppressive agents, such as azathioprine, methotrexate, cyclophosphamide, and total lymphoid irradiation, have been tried in inclusion body myositis body myositis without definitive improvement. A randomized, controlled trial confirmed a lack of benefit for methotrexate (13). A patient who has been referred to a tertiary neuromuscular center with a diagnosis of polymyositis and who has failed to respond to all immunotherapies most likely has inclusion body myositis body myositis or, rarely, another disease.

Improvement in three patients with inclusion body myositis body myositis treated with cyclosporine or tacrolimus has been also reported (131). However, it is not clear that these patients truly had inclusion body myositis body myositis; none had rimmed vacuoles on their muscle biopsies and the description of physical findings did not mention quadriceps or finger flexor weakness.

Intravenous immunoglobulin has been assessed in a number of studies. A double-blind, placebo-controlled trial of IVIg found no statistical difference in manual muscle testing scores (54). The addition of prednisone to IVIg also produced no benefit (50). IVIg resulted, however, in significant improvement of dysphagia (54; 27; 46). Another double-blind, placebo-controlled study of IVIg in 22 patients with inclusion body myositis body myositis found statistically significant improvement using a subjective symptom scale but not by objective motor strength testing (159); a trend toward slowed progression while on IVIg therapy was noted. Definite, but non-sustained, benefits of IVIg have also been demonstrated after a long-term therapy of 23 months (61). Such transient benefits are similar to those seen in various other autoimmune diseases, where immune and degenerative features coexist from the outset. For example, patients with primary progressive multiple sclerosis behave to some degree like patients with inclusion body myositis body myositis because some of them may partially respond early in the disease, but then they follow a steadily progressive course resistant to most therapies. An explanation for the resistance of the disease to IVIg and prednisone has been provided based on molecular studies performed in these patients’ repeated muscle biopsies (50); it was found that IVIG and prednisone reduce some inflammatory and degenerative molecules in the patients' muscle, but do not sufficiently suppress myotoxic and cell stress mediators such as nitric oxide (163). A small and uncontrolled study using subcutaneous immunoglobulin demonstrated some benefit in patients with inclusion body myositis body myositis if given for a longer-term period (26).

In a double-blind, placebo-controlled, crossover trial involving 19 patients, the anabolic steroid oxandrolone produced a significant improvement in upper extremity strength when measured with quantitative muscle testing (135). Oxandrolone was well tolerated. A similar-sized, randomized trial of antithymocyte globulin also demonstrated small, but statistically significant, improvement on quantitative muscle testing (101). Although these two studies are encouraging, they were small, and larger confirmatory studies are needed.

A multicenter, placebo-controlled study with 30 µg per week of beta-interferon 1a showed no change in disease progression (116). A similar study using a higher dose of this medication was also negative (117). A pilot study with simvastatin showed no benefits but also no statin-related worsening (139).

The noted interrelationship between inflammatory mediators and degeneration suggests that successful suppression of endomysial inflammation may have an effect on some degeneration-associated molecules inducing short-term clinical stability. This view led us to perform a proof-of-principle uncontrolled study with alemtuzumab, a T-cell-depleting monoclonal antibody (51). The study showed that depletion of T cells from the periphery also caused reduction of T cells in the muscle, with suppression of some degeneration-associated molecules resulting in a 6-month disease stability period. Although no substantial improvement in strength was noted to justify the use of this drug (now approved in multiple sclerosis), the study highlights that similar but more potent anti-inflammatory therapies, if proven safe for long-term therapy, may have an effect not only on inflammatory mediators but also in halting degeneration (40; 41; 143; 144; 145; 70).

Because in inclusion body myositis body myositis IL-1β, a potent proinflammatory cytokine secreted by monocytes and macrophages, colocalizes with amyloid precursor protein and upregulates amyloid aggregates enhancing degeneration (39; 141), targeting IL-1β might arrest disease progression. On this basis, a small pilot trial with anakinra, a nonselective IL1-receptor antagonist that blocks the biological activity of interleukin-1b, was conducted but failed to show any benefit (93). A follow-up study with canakinumab, a target-specific blocker of interleukin-1b receptor, also failed to improve strength or arrest disease progression for up to a year of treatment (94).

Although the resistance of inclusion body myositis body myositis to these immunotherapies has raised concerns that the degenerative process rather than the inflammatory one might be more relevant, a number of reasons may explain the lack of efficacy of such treatments (143; 144; 40; 41). Firstly, therapy is always initiated late, when the degenerative cascade has already begun, due to the insidious nature of the disease and very slow progression. It is striking that even patients with minimal clinical weakness, who seek medical attention relatively early, already exhibit muscle atrophy and advanced histological changes. The observation that alpha B-crystallin is, along with proinflammatory markers, an early event associated with cell stress response that precedes accumulation of beta amyloid supports the view that anti-inflammatory therapy can not only arrest progression if initiated early, but may even lead to complete remission, as shown in one well documented and remarkable case (97). Secondly, the production of proinflammatory mediators by the muscle fibers themselves may pose a problem in arresting the process because the standard immunosuppressants may not be able to suppress the transcription factors that trigger the continuous production of cytokines by the muscle fibers themselves (40; 41; 143; 144; 145). Thirdly and most importantly, as data suggest (70) and as already has been mentioned, agents targeting highly differentiated cytotoxic T cells and not those exerting a broad nonselective lymphocyte depletion might be more promising because the autoimmunity in inclusion body myositis body myositis is rather distinct, characterized by highly differentiated nonproliferating cytotoxic T cell phenotypes (51; 70). A single case report showed that alemtuzumab led to stabilization of a patient symptoms up to 2 years (136).

All the current trials with nonimmune-related agents have also been disappointing. Most notable among them is the trial targeting muscle-inhibiting TGF-β molecules or muscle growth factors using bimagrumab, a monoclonal antibody that binds to muscle activin-2 receptors with greater affinity than their natural ligands activin and myostatin, which function as negative regulators of muscle growth. By inhibiting myostatin, bimagrumab can increase muscle weight in mice and cultured myotubes but has no demonstrable effect on increasing muscle strength. On this background, a large, controlled study was performed with 251 patients randomized to receiving monthly bimagrumab or placebo for 52 weeks. No change in 6-minute walk test, the study’s primary endpoint, was noted compared to placebo; all enrolled patients continued to worsen with further deterioration in quantitative muscle strength testing, more falls, and worsening swallowing (76). This was the largest clinical trial in patients with inclusion body myositis body myositis but the most disappointing. Even the long-term extension study (RESILIENT) was negative (02).

A small, controlled, proof-of-concept study of arimoclomol, an agent that upregulates heat shock protein response and attenuates cell stress, was conducted in 24 patients (16 randomized to receive arimoclomol and 8 placebo) (108). The drug, which had resulted in some improved pathology in the mutant valosin-containing protein mouse (used as a model of inclusion body myositis body myositis), did not show any significant evidence of clinical efficacy in the study patients (01). A randomized placebo-controlled study of 152 participants randomly assigned to arimoclomol (n=74) or placebo (n=78) showed no efficacy, not an unexpected finding considering the very weak scientific basis to explore this drug in inclusion body myositis (109).

Intramuscular injection of an isoform of follistatin (FS344) by adeno-associated virus AAV1 (rAAV1.CMV. huFS344) delivered to the quadriceps muscles of both legs in six patients with inclusion body myositis body myositis showed some gains in muscle function (111). However, the results were preliminary, and it is unclear if further larger scales studies are planned. A controlled study with rapamycin has also been conducted and reported as being negative, but it has not yet been published.

Both supportive and symptomatic therapies are essential in inclusion body myositis body myositis patients. Close monitoring of dysphagia and early initiation of speech therapy to aid in swallowing techniques and prevent aspiration are important. In severely dysphagic patients, botulinum toxin injections into or surgical section of the cricopharyngeal muscle may be beneficial (55; 56; 78; 103; 46). Botulinum neurotoxin A injections to the cricopharyngeal muscle in 12 patients were reported to alleviate dysphagia and reduce the rate of aspiration (147). As mentioned earlier, IVIg can be effective in improving dysphagia based on several studies and it is the preferable therapy of this author. Physical and occupational therapy are helpful to maintain functional capacity, especially as related to ambulation and hand use. A nonfatiguing, resistance exercise program has also been shown to be of some benefit to patients with inclusion body myositis body myositis and is advisable (154). Occupational and rehabilitation therapies can be useful by offering devices to improve ambulation and provide assistance on how best to walk without falling, ie, “locking” on the knees or using light braces. Falling is frequent and, thus, protective measures should be taken early in the disease to avoid fractures and prolonged immobilization of a limb.

Media

References

01: Ahmed M, Machado PM, Miller A, et al. Targeting protein homeostasis in sporadic inclusion body myositis. Sci Transl Med 2016;8(331):331ra41. PMID 27009270
02: Amato AA, Hanna MG, Machado PM, et al. Efficacy and safety of bimagrumab in sporadic inclusion body myositis: long-term extension of RESILIENT. Neurology 2021;96(12):e1595-607. PMID 33597289
03: Amemiya K, Granger RP, Dalakas MC. Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. Brain 2000;123:2030-9. PMID 11004120
04: Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984;16:193-208. PMID 6383191
05: Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. IV: cell-mediated cytotoxicity and muscle fiber necrosis. Ann Neurol 1988;23:168-73. PMID 3288082
06: Argov Z, Yarom R. “Rimmed vacuole myopathy” sparing the quadriceps. A unique disorder in Iranian Jews. J Neurol Sci 1984;64(1):33-43. PMID 6737002
07: Arnardottir S, Svanborg E, Borg K. Inclusion body myositis sensory dysfunction revealed with quantitative determination of somatosensory thresholds. Acta Neurol Scand 2003;108(1):22-7. PMID 12807389
08: Askanas V, Engel WK. Sporadic inclusion body myositis and hereditary inclusion-body myopathies: diseases of oxidative stress and aging. Arch Neurol 1998;55:915-20. PMID 9678308
09: Askanas V, Engel WK. Sporadic inclusion body myositis: conformational multifactorial ageing-related degenerative muscle disease associated with proteasomal and lysosomal inhibition, endoplasmic reticulum stress, and accumulation of amyloid-β42 oligomers and phosphorylated tau. Presse Med 2011;40(4 Pt 2):e219-35.** PMID 21392932
10: Askanas V, Engel WK, Alvarez RB. Light and electron microscopic localization of beta-amyloid protein in muscle biopsies of patients with inclusion body myositis. Am J Pathol 1992;141;31-6. PMID 1321564
11: Askanas V, Engel WK, Nogalska A. Inclusion body myositis: a degenerative muscle disease associated with intra-muscle fiber multi-protein aggregates, proteasome inhibition, endoplasmic reticulum stress and decreased lysosomal degradation. Brain Pathol 2009;19(3):493-506. PMID 19563541
12: Askanas V, Engel WK, Nogalska A. Sporadic inclusion body myositis: a degenerative muscle disease associated with aging, impaired muscle protein homeostasis and abnormal mitophagy. Biochim Biophys Acta 2015;1852(4):633-43. PMID 25241263
13: Badrising UA, Maat-Schieman ML, Ferrari MD, et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 2002;51(3):369-72. PMID 11891832
14: Badrising UA, Schreuder GM, Giphart MJ, et al. Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis. Neurology 2004;63(12):2396-8. PMID 15623710
15: Banwell BL, Engel AG. Alpha B-crystallin immunolocalization yields new insights into inclusion body myositis. Neurology 2000;54(5):1033-41. PMID 10720271
16: Barkhaus PE, Periquet MI, Nandedkar SD. Quantitative electrophysiologic studies in sporadic inclusion body myositis. Muscle Nerve 1999;22:480-7. PMID 10204783
17: Barohn RJ, Amato AA, Sahenk Z, Kissel JT, Mendell JR. Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology 1995;45(7):1302-4. PMID 7617187
18: Bhatt PS, Tzoulis C, Balafkan N, et al. Mitochondrial DNA depletion in inclusion body myositis. Neuromuscul Disord 2019;29(3):242-6. PMID 30850168
19: Blume G, Pestronk A, Bennett F, Johns DR. Polymyositis with cytochrome oxidase negative muscle fibers: early quadriceps weakness and poor response to immunosuppressive therapy. Brain 1997;120:39-45. PMID 9055796
20: Bradshaw EM, Orihuela A, McArdel SL, et al. A local antigen-driven humoral response is present in the inflammatory myopathies. J Immunol 2007;178(1):547-56. PMID 17182595
21: Brannagan TH, Hays AP, Lange DJ, Trojaborg W. The role of quantitative electromyography in inclusion body myositis. J Neurol Neurosurg Psychiatry 1997;63:776-9. PMID 9416815
22: Carpenter S, Karpati G, editors. Pathology of skeletal muscle. New York: Churchill Livingstone, 1984.
23: Carpenter S, Karpati G, Heller I, Eisen A. Inclusion body myositis: a distinct variety of idiopathic inflammatory myopathy. Neurology 1978;28(1):8-17. PMID 201886
24: Carpenter S, Karpati G, Wolff L. Virus-like filaments and phospholipid accumulation in skeletal muscle: study of a histochemically distinct chronic myopathy. Neurology 1970;20:889-903. PMID 5466457
25: Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 2008;70(6):418-24. PMID 17881720
26: Cherin P, Belizna C, Cartry O, et al. Long-term subcutaneous immunoglobulin use in inflammatory myopathies: A retrospective review of 19 cases. Autoimmun Rev 2016;15(3):281-6. PMID 26688441
27: Cherin P, Pelletier S, Teixeira A, et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology 2002;58(2):326. PMID 11805271
28: Chou SM. Myxovirus-like structures in a case of chronic polymyositis. Science 1967;158:1453-5. PMID 6058682
29: Chou SM. Inclusion body myositis: a chronic persistent mumps myositis. Hum Pathol 1986;17:765-77. PMID 3015764
30: Cox FM, Titulaer MJ, Sont JK, Wintzen AR, Verschuuren JJ, Badrising UA. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain. 2011;134(Pt 11):3167-75. PMID 21908393
31: Cupler EJ, Leon-Monzon M, Miller J, Semino-Mora C, Anderson TL, Dalakas MC. Inclusion body myositis in HIV-1 and HTLV-1 infected patients. Brain 1996;119(Pt 6):1887-93. PMID 9009995
32: Dalakas MC. Autoimmune inflammatory myopathies. Handb Clin Neurol 2023;195:425-60. PMID 37562881
33: Dalakas MC. Polymyositis, dermatomyositis, and inclusion body myositis. N Engl J Med 1991;325:1487-98. PMID 1658649
34: Dalakas MC. Inflammatory, immune, and viral aspects of inclusion body myositis. Neurology 2006a;66(2 Suppl 1):S33-8. PMID 16432143
35: Dalakas MC. Sporadic inclusion body myositis--diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol 2006b;2(8):437-47. PMID 16932602
36: Dalakas MC. Interplay between inflammation and degeneration: using inclusion body myositis to study “neuroinflammation.” Ann Neurol 2008;64(1):1-3. PMID 18626972
37: Dalakas MC. Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol 2010a;6(3):129-37. PMID 20125096
38: Dalakas MC. Inflammatory muscle diseases: a critical review on pathogenesis and therapies. Curr Opin Pharmacol 2010b;10(3):346-52. PMID 20409756
39: Dalakas MC. Molecular immunology and genetics of inflammatory muscle diseases. Arch Neurol 1998;55(12):1509-12. PMID 9865793
40: Dalakas MC. Pathophysiology of inflammatory and autoimmune myopathies. Press Med 2011a;40(4 Pt 2):e237-47. PMID 21411269
41: Dalakas MC. Immunotherapy of inflammatory myopathies: practical approach and future prospects. Curr Treat Options Neurol 2011b;13(3):311-23. PMID 21365201
42: Dalakas MC. Review: An update on inflammatory and autoimmune myopathies. Neuropathol Appl Neurobiol 2011c;37(3):226-42. PMID 21155862
43: Dalakas MC. Inflammatory muscle diseases. N Engl J Med 2015;372(18):1734-47.** PMID 25923553
44: Dalakas MC. Inflammatory myopathies: update on diagnosis, pathogenesis and therapies, and COVID-19-related implications. Acta Myol 2020;39(4):289-301.** PMID 33458584
45: Dalakas MC. Non-convincing evidence of SARS-CoV-2-related myositis in autopsied muscles. JAMA Neurology 2021.
46: Dalakas MC. Complement in autoimmune inflammatory myopathies, the role of myositis-associated antibodies, COVID-19 associations, and muscle amyloid deposits. Expert Rev Clin Immunol 2022;18(4):413-23. PMID 35323101
47: Dalakas MC, Illa I. Common variable immunodeficiency and inclusion body myositis: a distinct myopathy mediated by natural killer cells. Ann Neurol 1995;37(6):806-10. PMID 7778855
48: Dalakas MC, Illa I, Gallardo E, Juarez C. Inclusion body myositis and paraproteinemia: incidence and immunopathologic correlations. Ann Neurol 1997a;41(1):100-4. PMID 9005871
49: Dalakas MC, Karpati G. The inflammatory myopathies. In: Disorders of voluntary muscle. Karpati G, Hilton-Jones D, Griggs RC, editors. Eighth edition. Cambridge University Press, 2010.
50: Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001;56(3):323-7. PMID 11171896
51: Dalakas MC, Rakocevic G, Schmidt J, et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion body myositis. Brain 2009;132(Pt 6):1536-44.** PMID 19454532
52: Dalakas MC, Rakocevic G, Shatunov A, Goldfarb L, Raju R, Salajegheh M. Inclusion body myositis with human immunodeficiency virus infection: four cases with clonal expansion of viral-specific T cells. Ann Neurol 2007;61(5):466-75.** PMID 17366634
53: Dalakas MC, Schmidt J. Viruses in IBM:Hit and run, hide and persist, or irrelevant? Neurology 2016;86(3):204-5. PMID 26683647
54: Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion body myositis with IVIg. Neurology 1997b;48(3):712-6. PMID 9065553
55: Danon MJ, Friedman M. Inclusion body myositis associated with progressive dysphagia: treatment with cricopharyngeal myotomy. Can J Neurol Sci 1989;16:436-8. PMID 2553229
56: Darrow DH, Hoffman HT, Barnes GJ, Wiley CA. Management of dysphagia in inclusion body myositis. Arch Otolaryngol Head Neck Surg 1992;118:313-7. PMID 1313247
57: De Bleecker JL, Meire VI, Declercq W, Van Aken EH. Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromuscul Disord 1999;9(4):239-46. PMID 10399751
58: De Paepe B, Creus KK, De Bleecker JL. Role of cytokines and chemokines in idiopathic inflammatory myopathies. Curr Opin Rheumatol 2009;21(6):610-6. PMID 19726994
59: De Paepe B, De Bleecker JL. The nonnecrotic invaded muscle fibers of polymyositis and sporadic inclusion body myositis: on the interplay of chemokines and stress proteins. Neurosci Lett 2013;535:18-23. PMID 23295907
60: Dimitri D, Benveniste O, Dubourg O, et al. Shared blood and muscle CD8+ T-cell expansions in inclusion body myositis. Brain 2006;129:986-95. PMID 16455793
61: Dobloug C, Walle-Hansen R, Gran JT, Molberg O. Long-term follow-up of sporadic inclusion body myositis treated with intravenous immunoglobulin: a retrospective study of 16 patients. Clin Exp Rheumatol 2012;30(6):838-42. PMID 22935197
62: Dobloug GC, Antal EA, Sveberg L, et al High prevalence of inclusion body myositis in Norway; a population-based clinical epidemiology study. Eur J Neurol 2015;22(4):672-e41. PMID 25530508
63: Eisen A, Berry K, Gobson G. Inclusion body myositis (IBM): myopathy or neuropathy. Neurology 1983;33:1109-14. PMID 6310442
64: Eisenberg I, Avidan N, Potikha T, et al. The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. Nat Genet 2001;29(1):83-7. PMID 11528398
65: Emslie-Smith AM, Arahata K, Engel AG. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol 1989;20(3):224-31.** PMID 2470663
66: Engel AG, Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984;16:209-15.** PMID 6089646
67: Ferrer I, Martin B, Castano JG, Lucas JJ, Moreno D, Olive M. Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis. J Neuropathol Exp Neurol 2004;63(5):484-98. PMID 15198127
68: Fratta P, Engel WK, Van Leeuwen FW, Hol EM, Vattemi G, Askanas V. Mutant ubiquitin UBB+1 is accumulated in sporadic inclusion body myositis muscle fibers. Neurology 2004;63(6):1114-7. PMID 15452314
69: Goyal NA, Coulis G, Duarte J, et al. Immunophenotyping of inclusion body myositis blood T and NK cells. Neurology 2022;98(13):e1374-83. PMID 35131904
70: Greenberg SA. Inclusion body myositis: clinical features and pathogenesis. Nat Rev Rheumatol 2019;15(5):257-72. PMID 30837708
71: Greenberg SA, Pinkus JL, Kong SW, Baecher-Allan C, Amato AA, Dorfman DM. Highly differentiated cytotoxic T cells in inclusion body myositis. Brain 2019;142(9):2590-604. PMID 31326977
72: Greenberg SA, Pinkus JL, Amato AA. Nuclear membrane proteins are present within rimmed vacuoles in inclusion body myositis. Muscle Nerve 2006;34(4):406-16. PMID 16823856
73: Greenberg SA, Pinkus JL, Amato AA, Kristensen T, Dorfman DM. Association of inclusion body myositis with T cell large granular lymphocytic leukaemia. Brain 2016;139(Pt 5):1348-60. PMID 26920676
74: Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol 1995;38(5):705-13. PMID 7486861
75: Guttsches AK, Brady S, Krause K, et al. Proteomics of rimmed vacuoles define new risk allele in inclusion body myositis. Ann Neurol 2017;81(2):227-39. PMID 28009083
76: Hanna MG, Badrising UA, Benveniste O, et al. Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurol 2019;18(9):834-44. PMID 31397289
77: Hiniker A, Daniels BH, Margeta M. T-cell-mediated inflammatory myopathies in HIV-positive individuals: a histologic study of 19 cases. J Neuropathol Exp Neurol 2016;75(3):239-45. PMID 26843609
78: Houser SM, Calabrese LH, Strome M. Dysphagia in patients with inclusion body myositis. Laryngoscope 1998;108:1001-5. PMID 9665246
79: Huntley ML, Gao J, Termsarasab P, et al. Association between TDP-43 and mitochondria in inclusion body myositis. Lab Invest 2019;99(7):1041-8. PMID 30742062
80: Ikenaga C, Date H, Kanagawa M, et al. Muscle transcriptomics shows overexpression of cadherin 1 in inclusion body myositis. Ann Neurol 2022;91(3):317-28. PMID 35064929
81: Ivanidze J, Hoffmann R, Lochmuller H, Engel AG, Hohlfeld R, Dornmair K. Inclusion body myositis: laser microdissection reveals differential up-regulation of IFN-γ signaling cascade in attacked versus nonattacked myofibers. Am J Pathol 2011;179(3):1347-59. PMID 21855683
82: Joy JL, Oh SJ, Baysal AI. Electrophysiological spectrum of inclusion body myositis. Muscle Nerve 1990;13:949-51. PMID 2172812
83: Kallajoki M, Hyypia T, Halonen P, Orvell C, Rima BK, Kalimo H. Inclusion body myositis and paramyxoviruses. Hum Pathol 1991;22(1):29-32. PMID 1845865
84: Karpati G, O’Ferrall EK. Sporadic inclusion body myositis: pathogenic considerations. Ann Neurol 2009;65(1):7-11. PMID 19194875
85: Karpati G, Pouliot Y, Carpenter S. Expression of immunoreactive major histocompatibility complex products in human skeletal muscles. Ann Neurol 1988;23:64-72.** PMID 3278673
86: Karvelas K, Xiao T, Langefeld CD, et al. Assessing the accuracy of neuromuscular ultrasound for inclusion body myositis. Muscle Nerve 2019;59(4):478-81. PMID 30635914
87: Kayashima T, Matsuo H, Satoh A, et al. Nonaka myopathy is caused by mutations in the UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase gene (GNE). J Hum Genet 2002;47(2):77-9. PMID 11916006
88: Keller CW, Schmidt J, Lunemann JD. Immune and myodegenerative pathomechanisms in inclusion body myositis. Ann Clin Transl Neurol 2017;4(6):422-45. PMID 28589170
89: Kitazawa M, Green KN, Caccamo A, LaFerla FM. Genetically augmenting Abeta42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice. Am J Pathol 2006;168:1986-97. PMID 16723713
90: Kitazawa M, Trinh DN, LaFerla FM. Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3beta. Ann Neurol 2008;64(1):15-24. PMID 18318434
91: Koffman BM, Rugiero M, Dalakas MC. Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis. Muscle Nerve 1998a;21(1):115-7. PMID 9427231
92: Koffman BM, Sivakumar K, Simonis T, Stroncek D, Dalakas MC. HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myopathies. J Neuroimmunol 1998b;84(2):139-42. PMID 9628455
93: Kosmidis ML, Alexopoulos H, Tzioufas AG, Dalakas MC. The effect of anakinra, an IL1 receptor antagonist, in patients with inclusion body myositis (sIBM): a small pilot study. J Neurol 2013;334(1-2):123-5. PMID 23998706
94: Kosmidis ML, Pikazis D, Vlachoyiannopoulos P, Tzioufas A, Dalakas MC. Trial of Canakinumab, an IL-1β Receptor antagonist, in patients with inclusion body myositis. Neurol Neuroimmunol Neuroinflamm 2019;6(4):e581. PMID 31355317
95: Larman HB, Salajegheh M, Nazareno R, et al. Cytosolic 5’-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 2013;73(3):408-18. PMID 23596012
96: Laurent D, Riek J, Sinclair C, et al. Longitudinal changes in MRI muscle morphometry and composition in people with inclusion body myositis. Neurology 2022;99(9):e865-76. PMID 36038279
97: Layzer R, Lee HS, Iverson D, Margeta M. Dermatomyositis with inclusion body myositis pathology. Muscle Nerve 2009;40(3):469-71. PMID 19623629
98: Leff RL, Love LA, Miller FW, et al. Viruses in idiopathic inflammatory myopathies: absence of candidate viral genomes in muscle. Lancet 1992;399(8803):1192-5.** PMID 1349938
99: Leon-Monzon M, Dalakas MC. Absence of persistent infection with enteroviruses in muscles of patients with inflammatory myopathies. Ann Neurol 1992;32:219-22. PMID 1324633
100: Lindberg C, Oldfors A, Hedstrom A. Inclusion body myositis: peripheral nerve involvement. J Neurol Sci 1990;99:327-38. PMID 1964960
101: Lindberg C, Trysberg E, Tarkowski A, Oldfors A. Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology 2003;61(2):260-2. PMID 12874415
102: Lindgren U, Hedberg-Oldfors C, Pullerits R, Lindberg C, Oldfors A. Inclusion body myositis with early onset: a population-based study. J Neurol 2023;270(11):5483-92. PMID 37498322
103: Liu LW, Tarnopolsky M, Armstrong D. Injection of botulinum toxin A to the upper esophageal sphincter for oropharyngeal dysphagia in two patients with inclusion body myositis. Can J Gastroenterol 2004;18(6):397-9. PMID 15190396
104: Lotz BP, Engel AG, Nishino H, Stevens JC, Litchy WJ. Inclusion body myositis: observations in 40 patients. Brain 1989;112:727-47.** PMID 2543478
105: Luciano CA, Dalakas MC. Inclusion body myositis: no evidence for a neurogenic component. Neurology 1997;48:29-33.** PMID 9008489
106: Lunemann JD, Schmidt J, Schmid D, et al. Beta-amyloid is a substrate of autophagy in sporadic inclusion body myositis. Ann Neurol 2007;61(5):476-83. PMID 17469125
107: Lloyd TE, Christopher-Stine L, Pinal-Fernandez I, et al. Cytosolic 5’-Nucleotidase 1A as a target of circulating autoantibodies in autoimmune diseases. Arthritis Care Res (Hoboken) 2016;68(1):66-71. PMID 25892010
108: Machado P, Miller A, Herbelin L, et al. Safety and tolerability of arimoclomol in patients with sporadic inclusion body myositis: a randomised double-blind, placebo-controlled, phase IIa proof-of concept trial. Ann Rheum Dis 2013;72(Suppl 3):A164.
109: Machado PM, McDermott MP, Blaettler T, et al. Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2023;22(10):900-11. PMID 37739573
110: Mastaglia FL, Needham M, Scott A, et al. Sporadic inclusion body myositis: HLA-DRB1 allele interactions influence disease risk and clinical phenotype. Neuromuscul Disord 2009;19(11):763-5. PMID 19720533
111: Mendell JR, Sahenk Z, Al-Zaidy S, et al. Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes. Mol Ther 2017;25(4):870-9.** PMID 28279643
112: Mendell JR, Sahenk Z, Gales T, Paul L. Amyloid filaments in inclusion body myositis. Arch Neurol 1991;48:1229-34. PMID 1668977
113: Michelle H, Pinal-Fernandez I, Casal-Dominguez M, et al. Clinical subgroups and factors associated with progression in patients with inclusion body myositis. Neurology 2023;100(13):e1406-17. PMID 36690456
114: Mikol J, Felten-Papaiconomou A, Ferchal F, et al. Inclusion body myositis: clinicopathological studies and isolation of adenovirus type 2 from muscle biopsy specimen. Ann Neurol 1982;11(6):576-81. PMID 6287912
115: Murata K, Dalakas MC. Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies. Am J Pathol 1999;155(2):453-60. PMID 10433938
116: Muscle Study Group. Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis. Neurology 2001;57(9):1566-70. PMID 11706093
117: Muscle Study Group. Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis. Neurology 2004;63(4):718-20. PMID 15326251
118: Muth IE, Barthel K, Bahr M, Dalakas MC, Schmidt J. Proinflammatory cell stress in sporadic inclusion body myositis muscle: overexpression of alphaB-crystallin is associated with amyloid precursor protein and accumulation of beta-amyloid. J Neurol Neurosurg Psychiatry 2009;80(12):1344-9. PMID 19470495
119: Nagaraju K, Casciola-Rosen L, Lundberg I, et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum 2005;52(6):1824-35. PMID 15934115
120: Nalbantoglu J, Karpati G, Carpenter S. Conspicuous accumulation of a single-stranded DNA binding protein in skeletal muscle fibers in inclusion body myositis. Am J Pathol 1994;144(5):874-82. PMID 8178939
121: Needham M, Corbett A, Day T, Christiansen F, Fabian V, Mastaglia FL. Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. J Clin Neurosci 2008;15(12):1350-3.** PMID 18815046
122: Needham M, Mastaglia FL. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 2007;6(7):620-31.** PMID 17582362
123: Nishino H, Engel AG, Rima BK. Inclusion body myositis: the mumps virus hypothesis. Ann Neurol 1989;25:260-4. PMID 2729916
124: Nishino I, Noguchi S, Murayama K, et al. Distal myopathy with rimmed vacuoles is allelic to hereditary inclusion body myopathy. Neurology 2002;59(11):1689-93. PMID 12473753
125: Noto Y, Kondo M, Tsuji Y, et al. Diagnostic value of muscle [11C] PIB-PET in inclusion body myositis. Front Neurol 2020;10:1386. PMID 32010047
126: Olthoff A, Carstens PO, Zhang S, et al. Evaluation of dysphagia by novel real-time MRI. Neurology 2016;87(20):2132-8. PMID 27770070
127: Ozden S, Cochet M, Mikol J, Teixeira A, Gessain A, Pique C. Direct evidence for a chronic CD8+-T-cell-mediated immune reaction to tax within the muscle of a human T-cell leukemia/lymphoma virus type 1-infected patient with sporadic inclusion body myositis. J Virol 2004;78(19):10320-7. PMID 15367598
128: Peng A, Koffman BM, Malley JD, Dalakas MC. Disease progression in sporadic inclusion body myositis: observations in 78 patients. Neurology 2000;55:296-8.** PMID 10908910
129: Pluk H, van Hoeve BJ, van Dooren SH, et al. Autoantibodies to cytosolic 5'-nucleotidase IA in inclusion body myositis. Ann Neurol 2013;73(3):397-407. PMID 23460448
130: Pruitt JN 2nd, Showalter CJ, Engel AG. Sporadic inclusion body myositis: counts of different types of abnormal fibers. Ann Neurol 1996;39(1):139-43. PMID 8572661
131: Quartuccio L, De Marchi G, Scott CA, Ferraccioli G, Beltrami CA, De Vita S. Treatment of inclusion body myositis with cyclosporin-A or tacrolimus: successful long-term management in patients with earlier active disease and concomitant autoimmune features. Clin Exp Rheumatol 2007;25(2):246-51. PMID 17543149
132: Ray A, Amato AA, Bradshaw EM, et al. Autoantibodies produced at the site of tissue damage provide evidence of humoral autoimmunity in inclusion body myositis. PLoS One 2012;7(10):e46709. PMID 23071619
133: Rojana-Udomsart A, Bundell C, James I, et al. Frequency of autoantibodies and correlation with HLA-DRB1 genotype in sporadic inclusion body myositis (s-IBM): a population control study. J Neuroimmunol 2012;249(1-2):66-70. PMID 22554526
134: Rojana-Udomsart A, Needham M, Luo YB, et al. The association of sporadic inclusion body myositis and Sjögren's syndrome in carriers of HLA-DR3 and the 8.1 MHC ancestral haplotype. Clin Neurol Neurosurg 2011;113(7):559-63. PMID 21507567
135: Rutkove SB, Parker RA, Nardin RA, Connolly CE, Felice KJ, Raynor EM. A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology 2002;58(7):1081-7. PMID 11940697
136: Sá J, Costelha J, Marinho A. Inclusion body myositis treated with alemtuzumab. Eur J Case Rep Intern Med 2019;6(12):001368. PMID 31893209
137: Salajegheh M, Pinkus JL, Nazareno R, Amato AA, Parker KC, Greenberg SA. Nature of "Tau" immunoreactivity in normal myonuclei and inclusion body myositis. Muscle Nerve 2009;40(4):520-8. PMID 19626672
138: Salajegheh M, Rakocevic G, Raju R, Shatunov A, Goldfarb LG, Dalakas MC. T cell receptor profiling in muscle and blood lymphocytes in sporadic inclusion body myositis. Neurology 2007;69(17):1672-9. PMID 17954782
139: Sancricca C, Mora M, Ricci E, Tonali PA, Mantegazza R, Mirabella M. Pilot trial of simvastatin in the treatment of sporadic inclusion body myositis. Neurol Sci 2011;32(5):841-7. PMID 21695654
140: Sato T, Walker DL, Peters HA, Chou SM. Chronic polymyositis and myxovirus-like inclusions. Arch Neurol 1971;24:409-18. PMID 4324435
141: Schmidt J, Barthel K, Wrede A, Salajegheh M, Bahr M, Dalakas MC. Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain 2008;131(Pt 5):1228-40. PMID 18420712
142: Schmidt J, Barthel K, Zschüntzsch J, et al. Nitric oxide stress in sporadic inclusion body myositis muscle fibres: inhibition of inducible nitric oxide synthase prevents interleukin-1β-induced accumulation of β-amyloid and cell death. Brain 2012;135(Pt 4):1102-14.** PMID 22436237
143: Schmidt J, Dalakas MC. Pathomechanisms of inflammatory myopathies: recent advances and implications for diagnosis and therapies. Expert Opin Med Diagn 2010c;4(3):241-50. PMID 23488533
144: Schmidt J, Dalakas MC. Inclusion body myositis in the elderly: an update. Aging Health 2010d;6(6):687-94.
145: Schmidt J, Dalakas MC. Inclusion body myositis: from immunopathology and degenerative mechanisms to treatment perspectives. Expert Rev Clin Immunol 2013;9(11):1125-33. PMID 24138579
146: Schmidt J, Rakocevic G, Raju R, Dalakas MC. Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity. Brain 2004;127(Pt 5):1182-90. PMID 15047591
147: Schrey A, Airas L, Jokela M, Pulkkinen J. Botulinum toxin alleviates dysphagia of patients with inclusion body myositis. J Neurol Sci 2017;380:142-7. PMID 28870555
148: Scott AP, Laing NG, Mastaglia F, Needham M, Walter MC, Dalakas MC, Allcock RJ. Recombination mapping of the susceptibility region for sporadic inclusion body myositis within the major histocompatibility complex. J Neuroimmunol 2011;235(1-2):77-83. PMID 21543121
149: Sekul EA, Chow C, Dalakas MC. Magnetic resonance imaging of the forearm as a diagnostic aid in patients with inclusion body myositis. Neurology 1997;48(4):863-6. PMID 9109868
150: Sekul EA, Dalakas MC. Inclusion body myositis: new concepts. Semin Neurol 1993;13:256-63. PMID 8272596
151: Semino-Mora C, Dalakas MC. Rimmed vacuoles with beta-amyloid and ubiquitinated filamentous deposits in the muscles of patients with long-standing denervation (postpoliomyelitis muscular atrophy): similarities with inclusion body myositis. Human Pathol 1998;29(10):1128-33. PMID 9781653
152: Sivakumar K, Dalakas MC. The spectrum of familial inclusion body myopathies in 13 families and a description of a quadriceps sparing phenotype in non-Iranian Jews. Neurology 1996;47(4):977-84. PMID 8857730
153: Sivakumar K, Semino-Mora C, Dalakas MC. An inflammatory, familial, inclusion body myositis with autoimmune features and a phenotype identical to sporadic inclusion body myositis. Studies in three families. Brain 1997;120:653-61. PMID 9153127
154: Spector SA, Lemmer JT, Koffman BM, et al. Safety and efficacy of strength training in patients with sporadic inclusion body myositis. Muscle Nerve 1997;20(10):1242-8. PMID 9324080
155: Stathopoulos P, Dalakas MC. Autoimmune neurogenic dysphagia. Dysphagia 2022;37(3):473-87. PMID 34226958
156: Tawara N, Yamashita S, Zhang X, et al. Pathomechanisms of anti-cytosolic 5’-nucleotidase 1A autoantibodies in sporadic inclusion body myositis. Ann Neurol 2017;81(4):512-25. PMID 28318044
157: Uruha A, Noguchi S, Hayashi YK, et al. Hepatitis C virus infection in inclusion body myositis: a case-control study. Neurology 2016;86(3):211-7. PMID 26683644
158: Vasconcelos OM, Raju R, Dalakas MC. GNE mutations in an American family with quadriceps-sparing IBM and lack of mutations in s-IBM. Neurology 2002;59(11):1776-9. PMID 12473769
159: Walter MC, Lochmuller H, Toepfer M, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 2000;247(1):22-8. PMID 10701893
160: Watts GD, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 2004;36(4):377-81. PMID 15034582
161: Wiendl H, Hohlfeld R, Kieseier BC. Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends Immunol 2005;26(7):373-80.** PMID 15922662
162: Yunis EJ, Samaha FJ. Inclusion body myositis. Lab Invest 1971;25:240-8. PMID 5095321
163: Zschuntzsch J, Voss J, Creus K, et al. Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: quantitative assessment of inflammation and β-amyloid in the muscle. Arthritis Rheum 2012;64(12):4094-103. PMID 22941914

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Marinos C Dalakas MD

Dr. Dalakas of the National and Kapodistrian University of Athens Medical School in Greece and Thomas Jefferson University, Philadelphia, Pennsylvania received speaker honoraria and consultancy fees from Alexion, Argenx, Grifols, CSL, Sanofi, and UCB.
See Profile

Editor

Nicholas E Johnson MD MSCI FAAN

Dr. Johnson of Virginia Commonwealth University received consulting fees and/or research grants from AMO Pharma, Avidity, Dyne, Novartis, Pepgen, Sanofi Genzyme, Sarepta Therapeutics, Takeda, and Vertex, consulting fees and stock options from Juvena, and honorariums from Biogen Idec and Fulcrum Therapeutics as a drug safety monitoring board member.
See Profile

Former Authors

David S Saperstein MD
Emma Ciafaloni MD FAAN
Michael K Hehir MD

Patient Profile

Age range of presentation: 0 month to 65+ years
Sex preponderance: male>female, >2:1
Heredity: heredity may be a factor
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Myopathy, distal: 359.1

Myositis: 729.1
ICD-10: Myositis, unspecified: M60.9
OMIM: Myositis: %160750

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Inclusion body myositis

Associated Disorders

Chronic denervation
Collagen vascular diseases
Dermatomyositis
Familial inclusion body myositis
Infections
- Systemic immune-medicated disorders
- Vacuolar distal myopathies

Differential Diagnosis

polymyositis
distal myopathies with rimmed vacuoles
oculopharyngeal muscular dystrophy
Welander distal myopathy
distal myopathy with vacuolar formation
- dermatomyositis

Also Relevant

Dermatomyositis
Distal myopathies
Polymyositis, necrotizing autoimmune myositis, and fasciitis
Viral and retroviral myositis

Clinical Categories

Neuromuscular Disorders

Patient Handouts

Polymyositis

Inclusion-body myositis …

Inclusion body myositis

Introduction

Overview

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Biological basis

Etiology and pathogenesis

Epidemiology

Differential diagnosis

Diagnostic workup

Management

Media

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Distal myopathies

Amyotrophic lateral sclerosis

ALS-like disorders of the Western Pacific

Paraspinal neuromuscular syndromes

Dementia associated with amyotrophic lateral sclerosis

Collagen VI-related dystrophies: Ullrich congenital muscular dystrophy, Bethlem muscular dystrophy, and intermediate COL6-RD

Sleep and neuromuscular and spinal cord disorders

Periodic paralysis and the nondystrophic myotonias (skeletal muscle channelopathies)

Inclusion body myositis

Introduction

Overview

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Biological basis

Etiology and pathogenesis

Epidemiology

Differential diagnosis

Diagnostic workup

Management

Media

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Distal myopathies

Amyotrophic lateral sclerosis

ALS-like disorders of the Western Pacific

Paraspinal neuromuscular syndromes

Dementia associated with amyotrophic lateral sclerosis

Collagen VI-related dystrophies: Ullrich congenital muscular dystrophy, Bethlem muscular dystrophy, and intermediate COL6-RD

Sleep and neuromuscular and spinal cord disorders

Periodic paralysis and the nondystrophic myotonias (skeletal muscle channelopathies)

This is an article preview.
Start a Free Account
to access the full version.